SEMHF - Siemens Healthineers AG (SEMHF) Q1 2024 Earnings Call Transcript
2024-02-01 23:12:03 ET
Siemens Healthineers AG (SEMHF)
Q1 2024 Earnings Conference Call
February 1, 2024 02:30 ET
Company Participants
Marc Koebernick - Head, Investor Relations
Bernd Montag - Chief Executive Officer
Jochen Schmitz - Chief Financial Officer
Conference Call Participants
Graham Doyle - UBS
Veronika Dubajova - Citi
Julien Ouaddour - Bank of America
Hassan Al-Wakeel - Barclays
David Adlington - JPMorgan
Lisa Clive - Bernstein
Julien Dormois - Jefferies
Falko Friedrichs - Deutsche Bank
Robert Davies - Morgan Stanley
Presentation
Operator
Good morning, ladies and gentlemen and welcome to Siemens Healthineers Conference Call. As a reminder, this conference is being recorded. Before we begin, I would like to draw your attention to the Safe Harbor statement on Page 2 of the Siemens Healthineers presentation. This conference call may include forward-looking statements. These statements are based on the company’s current expectations and certain assumptions and are, therefore, subject to certain risks and uncertainties.
At this time, I would like to turn the call over to your host today, Mr. Marc Koebernick, Head of Investor Relations. Please go ahead, sir.
Marc Koebernick
Thank you, operator. Good morning, dear analysts and investors. Our CEO, Bernd Montag; and our CFO, Jochen Schmitz, who are here with me in our headquarters in Erlangen, will be taking you through the details of our Q1 2024 this morning. The Q1 results for fiscal ‘24 were published this morning at 7:00 a.m. and you can find all relevant documents as well as the recording of this call on the Investor Relations section of the Siemens Healthineers website. After the presentation, there will be a chance to raise questions. Please let me remind you of the two question rule for the Q&A.
So let us get started. Bernd, please go ahead.
Bernd Montag
Thank you, Marc. Good morning, dear analysts and investors. Let’s kick it off with a look at our outlook KPIs in Q1. We are off to a good start into fiscal year ‘24. We had strong comparable revenue growth ex antigen of 7% with the strongest growth contribution coming from Varian. Adjusted earnings per share came in at €0.49 in Q1 year-over-year, up by 5% ex antigen with strong EBIT contribution from conversion and the diagnostics transformation. With this good start, we reiterate our outlook for ‘24 with all KPIs, including the segment’s KPIs being on track. In the first quarter, we increased our order book lock once again with a very good equipment book-to-bill rate of 1.14....
Siemens Healthineers AG (SEMHF) Q1 2024 Earnings Call Transcript